Kuo Du

Has grant

Assistant Professor

University of Kansas Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Targeting Hepatocyte Senescence to Improve NAFLD

Open Date: 2024-03-01

Close Date: 2029-02-28

Grant: Close

Hippo-YAP Pathway, Ferroptosis of Hepatic Stellate Cells and Liver Fibrosis

Open Date: 2021-08-01

Close Date: 2024-07-01

Grant: Close

Pathophysiological Role of Glutaminolysis in Human NAFLD Progression

Open Date: 2018-07-01

Close Date: 2020-06-01

Articles (18)

Year:

2026

Year:

2026

Year:

2026

Background and Aims: Older age increases susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD) but whether it impacts response to therapies, and how the therapies impact regulators of biological aging, are poorly understood. Statins inhibit the mevalonate pathway to block cholesterol biosynthesis and are widely used in MASLD patients to reduce cardiovascular disease. Whether statins prevent progression to cirrhosis is under investigation. However, the molecular effects of statins in human liver, particularly in the context of aging, remain poorly defined. Approach and Results: We analyzed liver transcriptomes and matched clinical data from 368 adults enrolled in the Duke MASLD Biorepository with a focus on age-dependent responses and the interplay between senescence and ferroptosis, a regulated death process that is constrained by the mevalonate pathway. Serum ALT, AST, and LDL cholesterol levels were lower in statin users of both sexes, particularly among older individuals. Transcriptome analyses revealed that statin use strongly associated with suppression of senescence-related pathways. Statin use also associated with increased activation of pathways linked to ferroptosis. Both responses persisted after propensity score matching to control for clinical confounders and were validated in an independent obese cohort. Conclusions: Age-dependent transcriptional remodeling in the liver differs in statin users and non-users. Pathways involved in senescence are suppressed while those that promote ferroptosis are induced in statin users. These results suggest that statins may suppress biological aging in MASLD by acting as senolytics and highlight the complex, context-specific roles of senescence in liver adaptation and remodeling.

Year:

2026

Background Why alcohol-associated liver disease (ALD) resolves after abstinence in most people but progresses to liver failure in others remains poorly understood. Experimental models show that increased exposure to proinflammatory cytokines exacerbates ALD, yet clinical trials targeting these cytokines have failed. The tumour necrosis factor alpha (TNFα)-inducible zinc finger protein 36 (ZFP 36) family of RNA binding proteins controls the outcomes of TNFα exposure by destabilising suites of messenger RNAs (mRNAs) that execute the pleiotropic downstream actions of TNFα. Objective To investigate the role of RNA binding protein ZFP36 ring finger protein like 1 (ZFP36L1) in regulating hepatocyte fate and its contribution to the progression of ALD. Design We selectively deleted ZFP36L1 in mouse hepatocytes to assess its impact on ALD progression, transcriptional reprogramming, senescence and direct mRNA targets. In parallel, we analysed human liver explants to evaluate ZFP36L1 in relation to hepatocyte senescence, disease severity and zinc-dependent regulation. Results Deletion of ZFP36L1 exacerbated experimental ALD and activated transcriptional programmes driving ductal transdifferentiation, inflammation and senescence. Mechanistically, ZFP36L1 directly destabilised cyclin-dependent kinase inhibitor 1A (Cdkn1a)(p21) and jagged canonical notch ligand 1 (Jag1) mRNAs, thereby suppressing hepatocyte senescence and JAG1-NOTCH signalling. In human liver explants, ZFP36L1 activity declined in parallel with increasing hepatocyte senescence and ALD severity and was closely associated with impaired zinc-dependent signalling. Manipulation of zinc availability altered ZFP36L1 activity and expression of its direct targets. Conclusion These findings uncover a zinc-dependent ZFP36L1-regulon that governs hepatocyte fate by repressing p21- and JAG1-driven senescence and NOTCH activation and highlight ZFP36L1 as a promising therapeutic target in ALD.

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (13)

Ayako Suzuki

Duke University

UNITED STATES
View details

Anna Mae Diehl

Duke University

UNITED STATES
View details

Dennis Ko

Associate Professor with Tenure

Duke University

UNITED STATES
View details

Ji Hye Jun

Assistant Professor

Gyeongsang National University

SOUTH KOREA
View details

Jen-Tsan Chi

Duke University

UNITED STATES
View details

David Umbaugh

Postdoctoral Associate

Duke University

UNITED STATES
View details

Liuyang Wang

Research Associate Professor

Duke University

UNITED STATES
View details

Joseph Locker

Professor

University of Pittsburgh

UNITED STATES
View details

Shannan Ho Sui

Principal Research Scientist

Harvard T.H. Chan School of Public Health

UNITED STATES
View details

Wolfram Goessling

Chair of Medicine

Yale University

UNITED STATES
View details

Lu Wang

Assistant Professor

UT Health San Antonio

UNITED STATES
View details

Rajesh Kumar Dutta

Research Associate, Senior

Duke University

UNITED STATES
View details

Terje Johansen

Professor

UiT Norges arktiske universitet

NORWAY
View details